Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection

Journal of Proteome Research

Volumn 13, Issue 10, 2014, Pages 4356-4362

  Dharmasiri, Udara ^a,c   Isenberg, Samantha L ^b   Glish, Gary L ^b   Armistead, Paul M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c ENTEGRIS INC   (United States)

Author keywords

cancer antigen; Differential ion mobility spectrometry; DIMS; FAIMS; mass spectrometry

Indexed keywords

CG1 ANTIGEN; LEUKEMIA ANTIGEN; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; CHEMICAL MODEL; CONTROLLED STUDY; DIFFERENTIAL ION MOBILITY SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ION MOBILITY SPECTROMETRY; LEUKEMIA CELL LINE; TANDEM MASS SPECTROMETRY; ALGORITHM; IMMUNOLOGY; LEUKEMIA; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ALGORITHMS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; LEUKEMIA; MODELS, CHEMICAL; TANDEM MASS SPECTROMETRY;

EID: 84907855796     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500527c     Document Type: Article

References (44)

1. Hatsis, P.; Valaskovic, G.; Wu, J. T. Online nanoelectrospray/high-field asymmetric waveform ion mobility spectrometry as a potential tool for discovery pharmaceutical bioanalysis Rapid Commun. Mass Spectrom. 2009, 23, 3736-42
2. Kolakowski, B. M.; Mester, Z. Review of applications of high-field asymmetric waveform ion mobility spectrometry (FAIMS) and differential mobility spectrometry (DMS) Analyst 2007, 132, 842-64
3. Xia, Y. Q.; Wu, S. T.; Jemal, M. LC-FAIMS-MS/MS for quantification of a peptide in plasma and evaluation of FAIMS global selectivity from plasma components Anal. Chem. 2008, 80, 7137-43
4. Eiceman, G.; Karpas, Z. Ion Mobility Spectrometry; CRC Press: Boca Raton, FL, 2005.
5. Mason, E. A.; McDaniel, E. W. Transport Properties of Ions in Gases; John Wiley & Sons, Inc.: New York, 1988.
6. Hinrichs, C. S.; Restifo, N. P. Reassessing target antigens for adoptive T-cell therapy Nat. Biotechnol. 2013, 31, 999-1008
7. Jensen, P. E. Recent advances in antigen processing and presentation Nat. Immunol 2007, 8, 1041-8
8. Neefjes, J.; Jongsma, M. L.; Paul, P.; Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation Nat. Rev. Immunol. 2011, 11, 823-36
9. Phan, G. Q.; Rosenberg, S. A. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy Cancer Control 2013, 20, 289-97
10. George, S.; Pili, R.; Carducci, M. A.; Kim, J. J. Role of immunotherapy for renal cell cancer in 2011 J. Natl. Compr. Cancer Network 2011, 9, 1011-8
11. Michael, A.; Relph, K.; Annels, N.; Pandha, H. Prostate cancer vaccines Expert Rev. Vaccines 2013, 12, 253-62
12. Rezvani, K.; de Lavallade, H. Vaccination strategies in lymphomas and leukaemias: recent progress Drugs 2011, 71, 1659-74
13. Linette, G. P.; Stadtmauer, E. A.; Maus, M. V. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Blood 2013, 122, 863-71
14. Warren, E. H.; Fujii, N.; Akatsuka, Y. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens Blood 2010, 115, 3869-78
15. den Haan, J. M.; Meadows, L. M.; Wang, W. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism Science 1998, 279, 1054-7
16. den Haan, J. M.; Sherman, N. E.; Blokland, E. Identification of a graft versus host disease-associated human minor histocompatibility antigen Science 1995, 268, 1476-80
17. Fortier, M. H.; Caron, E.; Hardy, M. P. The MHC class I peptide repertoire is molded by the transcriptome J. Exp. Med. 2008, 205, 595-610
18. Mohammed, F.; Cobbold, M.; Zarling, A. L. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self Nat. Immunol. 2008, 9, 1236-43
19. Papadopoulos, K. P.; Suciu-Foca, N.; Hesdorffer, C. S.; Tugulea, S.; Maffei, A.; Harris, P. E. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts Blood 1997, 90, 4938-46
20. van Bergen, C. A.; Kester, M. G.; Jedema, I. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene Blood 2007, 109, 4089-96
21. Gallegos, A. M.; Bevan, M. J. Central tolerance: good but imperfect Immunol. Rev. 2006, 209, 290-6
22. Hoof, I.; Peters, B.; Sidney, J. NetMHCpan, a method for MHC class I binding prediction beyond humans Immunogenetics 2009, 61, 1-13
23. Lundegaard, C.; Lamberth, K.; Harndahl, M.; Buus, S.; Lund, O.; Nielsen, M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11 Nucleic Acids Res. 2008, 36, W509-12
24. Nielsen, M.; Lundegaard, C.; Lund, O.; Kesmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage Immunogenetics 2005, 57, 33-41
25. Nielsen, M.; Lundegaard, C.; Worning, P. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations Protein Sci. 2003, 12, 1007-17
26. Rammensee, H. G.; Bachmann, J.; Emmerich, N. N.; Bachor, O. A.; Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 1999, 50, 213-9
27. Robbins, P. F.; Lu, Y. C.; El-Gamil, M. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat. Med. 2013, 19, 747-52
28. Pang, C. N.; Tay, A. P.; Aya, C. Tools to covisualize and coanalyze proteomic data with genomes and transcriptomes: validation of genes and alternative mRNA splicing J. Proteome Res. 2014, 13, 84-98
29. Rodriguez-Cruz, T. G.; Liu, S.; Khalili, J. S. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity PLoS One 2011, 6, e22939
30. Zhang, M.; Sukhumalchandra, P.; Enyenihi, A. A. A novel HLA-A∗0201 restricted peptide derived from cathepsin G Is an effective immunotherapeutic target in acute myeloid leukemia Clin. Cancer Res. 2013, 19, 247-57
31. Princiotta, M. F.; Finzi, D.; Qian, S. B. Quantitating protein synthesis, degradation, and endogenous antigen processing Immunity 2003, 18, 343-54
32. Yewdell, J. W.; Reits, E.; Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation Nat. Rev. Immunol. 2003, 3, 952-61
33. Krylov, E. V.; Coy, S. L.; Vandermey, J.; Schneider, B. B.; Covey, T. R.; Nazarov, E. G. Selection and generation of waveforms for differential mobility spectrometry Rev. Sci. Instrum. 2010, 81, 024101
34. Isenberg, S. L.; Armistead, P. M.; Glish, G. L. Optimization of peptide separations by differential ion mobility spectrometry J. Am. Soc. Mass Spectrom. 2014, 25, 1592-9
35. Del Monte, U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 2009, 8, 505-6
36. Mittendorf, E. A.; Clifton, G. T.; Holmes, J. P. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Cancer 2012, 118, 2594-602
37. Rezvani, K.; Yong, A. S.; Mielke, S. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood 2008, 111, 236-42
38. Hunsucker, S. A.; McGary, C. S.; Vincent, B. G. Mapping of Antigen-Specific T-Cell Receptor Sequences to T-Cell Receptor Repertoires Measures Antigen-Driven, Clonal T-cell Expansion. Cancer Immunol. Res. 2014, under revision
39. Lin, T.; Glish, G. L. C-terminal peptide sequencing via multistage mass spectrometry Anal. Chem. 1998, 70, 5162-5
40. Lin, T.; Payne, A. H.; Glish, G. L. Dissociation pathways of alkali-cationized peptides: opportunities for C-terminal peptide sequencing J. Am. Soc. Mass Spectrom. 2001, 12, 497-504
41. Chapuis, A. G.; Ragnarsson, G. B.; Nguyen, H. N. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients Sci. Transl. Med. 2013, 5, 174ra27
42. Meij, P.; Jedema, I.; van der Hoorn, M. A. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study Haematologica 2012, 97, 1205-8
43. Rezvani, K.; Yong, A. S.; Mielke, S. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies Haematologica 2011, 96, 432-40
44. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013; 368: 2059-74.